FAQs
Overview
Is it sufficient to send in one application for a multi-centre trial?
In the case of a multi-centre investigation one application is sufficient.
When a sponsor reports a serious adverse reaction into the EudraVigilance database with IMCA and EMEA as recipients, does the report appear twice?
No, the adverse reaction is only reported once into the European database EudraVigilance.
